Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

What's New in Onychomycosis?

Description

The presentation on onychomycosis highlights recent developments in its epidemiology, emphasizing various forms of the condition, such as distal and lateral subungual onychomycosis, white superficial onychomycosis, and mixed infections consisting of dermatophytes and non-dermatophyte molds. The speaker notes that onychomycosis affects different population demographics, with higher prevalence in the elderly and specific at-risk groups like diabetics and immunocompromised individuals. Recent studies show that non-dermatophyte molds, particularly affecting females, pose distinct treatment challenges as they typically respond less effectively than dermatophyte infections. A notable point discussed is the examination of PCR-positive and histopathological samples to accurately identify the causative organisms, essential for guiding effective treatment. The speaker warns that while often viewed as a benign condition, onychomycosis can lead to severe complications in vulnerable patients. This underscores the need for thorough testing and accurate diagnosis in managing these fungal nail infections.

View more

Conclusions

  • Onychomycosis manifests in various forms, with distal and lateral subungual onychomycosis being the most common.
  • Children exhibit lower rates of onychomycosis, while the elderly and certain at-risk groups show higher prevalence.
  • Non-dermatophyte molds are detected more frequently in females compared to males.
  • A significant percentage of patients show mixed infections of dermatophytes and non-dermatophyte molds, particularly in Brazil.
  • In immunocompromised patients, onychomycosis can lead to systemic complications and even fatal outcomes.
  • Effective treatment of onychomycosis requires accurate identification of the causative organisms, as non-dermatophyte molds often respond poorly to standard therapies.
  • Testing for onychomycosis remains underutilized, with fewer than 25% of patients receiving diagnostic testing.
  • Gupta AK. et al. JEADV 2016;30(9):1567-72.
  • Tosti et al. ActaDermVenereol 1999; 79:52-53.
  • Gupta 2024 Mycoses PMID: 38606891
  • Gupta 2024. J Fungi. PMID: 39330393
  • Gupta et al. JAAD. 2012;66:494-502 .; Tosti et al. JAAD. 2000;42:217-24 .; De Doncker et al. JAAD. 1997;36:173-7.
  • Gupta et al. PLOS ONE. 2020 Sep 29;15(9):e0239648.
  • Boutati et al. Blood 1997;90(3):999-1008
  • Baran et al. BJD 2005; 153(5):1023-5.